CardioComm Solutions, Inc.'s Profile

The heartbeat of cardiovascular medicine and telemedicine. The company’s patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centers to access and manage patient information in a secure and reliable environment.
CardioComm Solutions, Inc.
Symbol
EKG
Exchange
TSX-V
Shares
146,893,262 as of 03/31/2020
Industry
Technology & Medical
Create a Post

Top Members

ADMINISTRATOR
Last Posted:
06/17/2021
Rating:
Messages:
143

CardioComm Solutions, Inc.'s Bulletin

Toronto, Ontario--(Newsfile Corp. - May 12, 2021) -  CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it has completed its previously announced issuance of shares for debt (see the Company's press releases dated April 27, 2021 and April 8, 2021 for further details). Under debt settlement agreements, the Company has issued an aggregate of 3,353,644 common shares of the Company ("Shares") to directors, employees and consultants of the Company to settle debt for services provided to the Company. The Shares are subject to a four month hold period that expires September 12, 2021, in accordance with the policies of the TSX Venture Exchange and applicable securities laws. Directors of the Company participated in the debt settlement transaction, which is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the transaction does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT:Etienne Grima, Chief Executive Officer1-877-977-9425 x227egrima@cardiocommsolutions.cominvestor.relations@cardiocommsolutions.com Forward-looking statementsThis release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  
Toronto, Ontario--(Newsfile Corp. - April 27, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced the proposed issuance of shares for debt and the issuance of stock options. Under debt settlement agreements, the Company will issue an aggregate of 2,947,394 common shares of the Company ("Shares") to a director, employees and consultants of the Company at a deemed price of $0.055 per Share. The Shares will be provided to settle debt for services provided to the Company and will be subject to a four month hold period in accordance with applicable securities laws. The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.055 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws. A director of the Company participated in the debt settlement and received stock options, each of which is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). Each transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT:Etienne Grima, Chief Executive Officer1-877-977-9425 x227egrima@cardiocommsolutions.cominvestor.relations@cardiocommsolutions.com Forward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced the proposed issuance of shares and the issuance of stock options. Under shares for debt agreements, the Company will issue an aggregate of 406,250 common shares of the Company ("Shares") to directors of the Company at a deemed price of $0.06 per Share. The Shares will be provided to settle debt for service expenses and will be subject to a four month hold period in accordance with applicable securities laws. The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.06 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws. To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT: Etienne Grima, Chief Executive Officer1-877-977-9425 x227egrima@cardiocommsolutions.cominvestor.relations@cardiocommsolutions.com Forward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CLIENT FEATURE: CardioComm Solutions (EKG: TSX-V) Has Finger On Pulse Of $149b mHealth Apps Market    Why CardioComm? CardioComm has 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers CardioComm Solutions has a unique position in the medical diagnostic industry as an FDA cleared, ISO certified and Health Canada/CE approved the company for the development, sale and marketing of medical software and devices. CardioComm Solutions owns its own source code, unlike its competitors who typically acquired source code licenses. CardioComm Solutions’ market advantage is that they are device agnostic allowing the CardioComm Solutions software to be plug and play with several different FDA-approved ECG recording devices. Any device that qualifies through their compliance program can be integrated into their system. Class II medical device clearances and device-agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health ECG solutions for both consumer (OTC) and medical (Rx) markets Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring     What Does CardioComm Do? CardioComm Solutions, Inc provides technically and clinically innovative software solutions for information management systems in cardiovascular medicine and telemedicine. CardioComm's patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment. EKG produces ECG solutions for both consumer (OTC) and medical (Rx) markets. An electrocardiogram (ECG) records the electrical signal from your heart to check for different heart conditions. The Company's software enables electrocardiography (ECG) data to be transmitted, received and managed anywhere in the world using standard computers, wireless devices, enterprise networks, telephones, or the Internet. Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring   Recent Highlights: February: CardioComm Solutions Expands ISO Clearance to Include Multiple Biosign Monitoring Device Integrations in Support of Remote Patient Monitoring Markets to include pulse oximetry ("PO2"), blood pressure ("BP"), weight and temperature in addition to ECG monitoring hardware and software solutions. As remote patient monitoring needs continue to grow so does the need for credible data to be collected from people outside of a hospital or medical office. Many patients are using vital sign/bio sign devices at home for measurements of heart rate, temperature, blood pressure and oxygen saturation. Having easy to use accurate devices is a crucial part of safe virtual care. January Appointment of a new Chief Financial Officer and completion of a debt to equity settlement. CardioComm Solutions, Inc. confirms the appointment of Ms. Josée Bertrand as the Company's Chief Financial Officer. Ms. Bertrand is an accomplished, results-driven senior accounting and financial management executive. She brings more than 30 years of progressive experience in finance and operations management in relevant industry sectors. Market Analysis: The global mHealth apps market size is expected to reach USD 149.3 billion by 2028 and is expected to register a CAGR of 17.7% over the forecast period, according to a new report by Grand View Research, Inc. Growing promotion of mHealth applications due to their benefits in improving lifestyle and treatment outcomes is one of the key factors driving the growth of this market. In addition, the use of mobile health applications can facilitate better patient experience and engagement.   The global market size is anticipated to be valued at USD 149.3 billion by 2028 owing to growing product adoption for better patient engagement and care  Based on type, the market is broadly classified into medical and fitness apps. The medical applications segment dominated the market in 2020 This is owing to high awareness levels about such applications and preference for their use by healthcare professionals, patients, and other consumers Medical applications are further classified into applications, such as women's health, medication management, personal health record, diagnostic, remote monitoring, disease management, and others North America led the global market in 2020; however, Asia Pacific is projected to become the fastest-growing regional market over the forecast period.   Who Uses CardioComm? Sold in >20 countries, with the largest customer base located in the US     Is CardioComm Approved? CardioComm Solutions has approval and clearance from the following :     $EKG $EKG.ca $ATE.ca $TLT.ca $ACST $IPA.ca $ARCH $NLH $WELL   CardioComm Solutions. is traded on the TSX.V as EKG.   For more information, visit: https://www.cardiocommsolutions.com/index.html   FULL DISCLOSURE: CardioComm Solutions is an advertising client of AGORA Internet Relations Corp.